Arbutus Biopharma Corporation (ABUS)
| Market Cap | 803.26M -11.4% |
| Revenue (ttm) | 181.72M +1,078.8% |
| Net Income | 153.05M |
| EPS | 0.79 |
| Shares Out | 197.85M |
| PE Ratio | 5.14 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,780,770 |
| Open | 3.980 |
| Previous Close | 3.880 |
| Day's Range | 3.870 - 4.075 |
| 52-Week Range | 3.500 - 5.450 |
| Beta | 0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About ABUS
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inh... [Read more]
Financial Performance
In 2025, Arbutus Biopharma's revenue was $14.08 million, an increase of 128.21% compared to the previous year's $6.17 million. Losses were -$33.50 million, -52.09% less than in 2024.
Financial StatementsNews
FDA lifts clinical hold on Arbutus Biopharma AB-101 IND application
Arbutus Biopharma (ABUS) announced that the company was notified by the FDA that the clinical hold on the investigational new drug, or IND, application for AB-101 has been removed and…
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease,...
Arbutus Biopharma commences $230M modified Dutch Auction tender offer
Arbutus Biopharma (ABUS) announced the commencement of a modified Dutch Auction tender offer to purchase for cancellation up to $230M in value of its common shares at a price of…
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...
Arbutus Biopharma to repurchase $230M of shares through Dutch Auction
Arbutus Biopharma (ABUS) announced plans to commence a modified “Dutch Auction” tender offer to repurchase up to $230M of its common shares at a purchase price of not less than…
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
Arbutus Biopharma Quarterly report: Q2 2026
Arbutus Biopharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Arbutus Biopharma Earnings release: Q2 2026
Arbutus Biopharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Arbutus Biopharma expects to return $230M in capital to shareholders
Arbutus is also announcing that it expects to return capital to shareholders commencing in Q3 through repurchases of up to approximately $230M of the company’s common shares, which repurchases may…
Arbutus initiates patent infringement actions against Pfizer, BioNTech
Arbutus Biopharma (ABUS) and its exclusive licensee, Genevant Sciences, a subsidiary of Roivant (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their...
Arbutus Biopharma receives $178M settlement agreement from Moderna
Arbutus (ABUS) also announced the receipt of approximately $178M from Moderna (MRNA), representing the company’s share of the noncontingent payment under the settlement agreement entered into with Mod...
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTec...
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
Arbutus Biopharma Quarterly report: Q1 2026
Arbutus Biopharma has published its Q1 2026 quarterly earnings report on May 13, 2026.
Arbutus Biopharma Earnings release: Q1 2026
Arbutus Biopharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Arbutus Biopharma granted Fast Track designation for imdusiran
Arbutus Biopharma (ABUS) announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABU...
Arbutus Biopharma Proxy statement: Proxy filing
Arbutus Biopharma filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Arbutus Biopharma Proxy statement: Proxy filing
Arbutus Biopharma filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies
Jefferies lowered the firm’s price target on Arbutus Biopharma (ABUS) to $5.50 from $7 and keeps a Buy rating on the shares. The key question post the Moderna (MRNA) settlement…
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
Arbutus Biopharma Earnings release: Q4 2025
Arbutus Biopharma released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.